<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03166904</url>
  </required_header>
  <id_info>
    <org_study_id>2017-05-097</org_study_id>
    <nct_id>NCT03166904</nct_id>
  </id_info>
  <brief_title>Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy</brief_title>
  <acronym>RICTOR_SC</acronym>
  <official_title>AZD2014 in RICTOR Amplified Solid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with RICTOR amplified refractory solid cancer will receive vistusertib(AZD2014).&#xD;
      Study-arm is composed of 27 patients.&#xD;
&#xD;
      Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle Tumour evaluation using&#xD;
      RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 8&#xD;
      weeks relative to the date of first dose, up to week 40, then every 16 weeks until objective&#xD;
      disease progression (within a window of +/- 7 days of the scheduled date).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with RICTOR amplified refractory solid cancer will receive vistusertib(AZD2014).&#xD;
      Study-arm is composed of 27 patients.&#xD;
&#xD;
      Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle Tumour evaluation using&#xD;
      RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 8&#xD;
      weeks relative to the date of first dose, up to week 40, then every 16 weeks until objective&#xD;
      disease progression (within a window of +/- 7 days of the scheduled date).&#xD;
&#xD;
      Study treatment will be continued until objective disease progression (unless other criteria&#xD;
      for treatment discontinuation are met). Patients may continue vistusertib(AZD2014) beyond&#xD;
      progression (according to RECIST 1.1), at the discretion of the investigator if they are&#xD;
      clinically benefiting from the treatment and they do not meet any other discontinuation&#xD;
      criteria.&#xD;
&#xD;
      If a patient discontinues study treatment prior to disease progression, they should continue&#xD;
      to be assessed using RECIST 1.1 until disease progression and then followed up for survival.&#xD;
&#xD;
      Assessments for survival should be made every 8 weeks following objective disease&#xD;
      progression. The details of first and subsequent therapies for cancer, after discontinuation&#xD;
      of treatment, will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of efficacy&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective reponse rate (ORR) by RECIST 1.1</measure>
    <time_frame>12months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>AZD2014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vistusertib(AZD2014)</intervention_name>
    <description>Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).</description>
    <arm_group_label>AZD2014</arm_group_label>
    <other_name>azd2014</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Advanced solid cancers (including histologically or cytologically documented gastric&#xD;
             cancer, colorectal cancer, hepatoma, biliary tract cancers, pancreatic cancer and rare&#xD;
             cancers.) that has progressed after standard chemotherapy.&#xD;
&#xD;
             - Rare cancers are defined as sarcoma, neuroendocrine carcinoma&#xD;
&#xD;
          2. Provision of tumor sample tumor sample tumor sample tumor sampletumor sample (from&#xD;
             either a resection or biopsy)&#xD;
&#xD;
          3. Patients with RICTOR amplification through NGS.&#xD;
&#xD;
          4. Patients are willing and able to comply with the protocol for the duration of the&#xD;
             study including undergoing treatment and scheduled visits and examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients not having received recommended treatment-lines and chemotherapy regimen for&#xD;
             the treatment of each tumor type in the advanced setting.&#xD;
&#xD;
          2. Any previous treatment with PIK3CA, AKT or mTOR inhibitor or agents with mixed PI3K /&#xD;
             mTOR activity.&#xD;
&#xD;
          3. HER2 positive AGC patients (defined by HER2 3+ by immunohistochemistry or HER2 SISH +)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jeeyun Lee</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

